Group 1: Market Overview - The Hang Seng Index experienced a decline, closing down 281 points or 1.05% at 26,563 points, marking a three-day losing streak with a total drop of 435 points or 1.61% [3] - The market opened lower, with a drop of 203 points, and at one point, the index fell to 26,533 points before slightly recovering after the announcement of China's GDP growth target [3] - The total market turnover for the day was 225.69 billion [3] Group 2: Sector Performance - Among 88 blue-chip stocks, 66 saw declines, with notable drops in pharmaceutical stocks such as China Biologic Products (down 6.2% to HKD 6.52), WuXi Biologics (down 4.8% to HKD 37.86), and Innovent Biologics (down 4.6% to HKD 85.35) [4] Group 3: Real Estate Market - In mainland China, the housing price index for 70 major cities fell by 2.7% year-on-year, marking the largest decline in five months [7] - In December, first-tier cities saw a year-on-year decline of 1.7% in new residential prices, with Shanghai experiencing a 4.8% increase while Beijing, Guangzhou, and Shenzhen saw declines of 2.4%, 4.8%, and 4.4% respectively [8] Group 4: Company News - Swire Properties announced a buyback of USD 400 million in notes due in 2026, aiming to optimize its capital structure while simultaneously issuing new notes [11] - KKCG Maritime proposed a public offer to acquire up to 52.13 million shares of Ferretti at a price of EUR 3.5 per share, which would increase its stake from 14.5% to 29.9% [12] - Luk Fook Holdings renewed its lease for a prime retail space in Causeway Bay at a monthly rent of HKD 750,000, reflecting a decrease of over 6% from the previous rental rate [13]

Report Summary 1. Industry Investment Rating No industry investment rating is provided in the report. 2. Core View The market is characterized by a structural trend. On January 19, the four major index futures contracts for the current month showed mixed performance. On the trading day, the total trading volume of index futures declined, indicating a decrease in investors' trading enthusiasm. The positions of the four major index futures also changed, with some increasing and some decreasing [1][2][3]. 3. Summary by Relevant Catalogs 3.1 Index Futures Data Tracking - **Closing Price and Fluctuation**: The closing prices of various index futures showed different degrees of increase or decrease. For example, the CSI 300 index closed at 4734.5, up 0.05%; the SSE 50 index closed at 3075.9, down 0.12%; the CSI 500 index closed at 8288, up 0.67%; and the CSI 1000 index closed at 8265.7, up 0.40% [1]. - **Basis**: The basis of different index futures and their contracts also varied. For instance, the basis of IF2602 was -1.66, and that of IH2602 was 0.46 [1]. - **Trading Volume and Open Interest**: The trading volume and open interest of each index futures contract changed. For example, the trading volume of IF2602 decreased by 5290 lots, and the open interest decreased by 1168 lots [1]. 3.2 Market Activity - **Trading Volume**: The total trading volume of index futures decreased. Specifically, the total trading volume of IF decreased by 34310 lots, IH by 18564 lots, IC by 21181 lots, and IM by 35971 lots [2]. - **Open Interest**: The total open interest of index futures also changed. The total open interest of IF decreased by 4289 lots, IH by 1610 lots, IC increased by 6196 lots, and IM increased by 1234 lots [3]. 3.3 Top 20 Member Positions The positions of the top 20 members in different index futures contracts changed. For example, in the IF2601 contract, the long - position decreased by 1007 lots, and the short - position decreased by 724 lots [5]. 3.4 Trend Intensity The trend intensity of IF and IH is 1, and that of IC and IM is also 1. The trend intensity ranges from - 2 to 2, with - 2 being the most bearish and 2 being the most bullish [6]. 3.5 Important Drivers - **A - share Market**: A - shares were in a shrinking and volatile state. The Shanghai Composite Index rose 0.29% to 4114 points, the Shenzhen Component Index rose 0.09%, the ChiNext Index fell 0.7%, and the total trading volume of A - shares was 2.73 trillion yuan, down from 3.06 trillion yuan the previous day [7]. - **Hong Kong Stock Market**: Hong Kong stocks opened lower and closed lower. The Hang Seng Index fell 1.05% to 26563.9 points, the Hang Seng Tech Index fell 1.24%, and the total trading volume was 2256.9 billion Hong Kong dollars, down from 2550.79 billion Hong Kong dollars the previous day [7]. - **Macroeconomic Data**: In 2025, China's GDP was 1401879 billion yuan, a 5% increase compared to the previous year. The national population at the end of 2025 was 1404890000, a decrease of 3390000 from the previous year, with a natural population growth rate of - 2.41‰ [7][8].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing significant capital inflow, indicating a potential favorable timing for investment in this sector as the innovative drug ETF (520880) shows strong performance despite recent declines [1][3][8]. Group 1: Market Performance - On January 19, the Hong Kong Stock Connect innovative drug ETF (520880) fell by 2.72%, marking three consecutive days of decline, yet recorded a net subscription of 85.51 million yuan, the highest single-day inflow in nearly a month [1][8]. - The latest fund size of the innovative drug ETF reached 2.296 billion yuan, maintaining a historical high with a total of 4.25 billion shares [4][11]. Group 2: Investment Opportunities - Short-term prospects for leading pharmaceutical companies are promising, with 2025 earnings forecasts potentially exceeding expectations, which could lead to valuation recovery opportunities [3][10]. - The first quarter is typically a peak period for overseas licensing transactions, making innovative drug companies with pipeline value, such as those with ADC, bispecific antibodies, and small RNA platforms, worthy of attention [3][10]. Group 3: Long-term Sector Logic - The core logic of the Hong Kong Stock Connect innovative drug sector remains robust, with expected overseas licensing totals for innovative drugs reaching 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [3][10]. - Continued policy support is anticipated, with the National Medical Products Administration (NMPA) expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the drug review and approval process [3][10]. Group 4: ETF Characteristics - The innovative drug ETF (520880) exclusively invests in innovative drug R&D companies, with over 73% of the top ten holdings representing leading firms in the sector, indicating a strong core strength [5][12][14]. - The ETF is designed to manage risks effectively by reducing the weight of less liquid component stocks, thereby controlling tail risks [6][13].

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by acquiring 1.345 million shares at an average price of HKD 90.0345 per share, totaling approximately HKD 121 million [1] - Following the acquisition, JPMorgan's total holdings in Innovent Biologics rose to 87,775,465 shares, increasing its ownership percentage from 4.98% to 5.06% [1]

Group 1 - The top three companies with net inflow of southbound funds are Alibaba-W (09988) with 1.954 billion, Tencent Holdings (00700) with 638 million, and China Construction Bank (00939) with 358 million [1][2] - The top three companies with net outflow of southbound funds are China Mobile (00941) with -883 million, Zijin Mining (02899) with -450 million, and Innovent Biologics (01801) with -435 million [1][2] - In terms of net inflow ratio, ICBC South China (03167) leads with 100.00%, followed by 361 Degrees (01361) with 78.85%, and Qin Port Co. (03369) with 67.10% [1][2] Group 2 - The top ten companies by net inflow include Alibaba-W (09988) with 1.954 billion and a closing price of 164.600, and Tencent Holdings (00700) with 638 million and a closing price of 622.000 [2] - The top ten companies by net outflow include China Mobile (00941) with -883 million and a closing price of 80.600, and Zijin Mining (02899) with -450 million and a closing price of 40.000 [2] - The top three companies by net inflow ratio also include South China Airlines (01055) with 59.53% and a closing price of 5.630 [3]

Market Overview - The A-share pharmaceutical and biotechnology index fell by 0.68%, underperforming the CSI 300 index by 0.11 percentage points and the ChiNext index by 1.97 percentage points, ranking 19th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index rose by 2.38%, outperforming the Hang Seng China Enterprises Index by 0.48 percentage points [4] R&D Progress - Last week, Qinhai Pharmaceutical's GH55 and Innovent Biologics' IBI343 clinical applications were newly undertaken [5] - Sangfor's 608 is currently in Phase III clinical trials; Aosaikang's ASK092 is in Phase II; and Hansoh Pharmaceutical's HS-20093 is in Phase I clinical trials [5] Industry Insights - The pharmaceutical and biotechnology sector is driven by innovation (including overseas expansion, AI, and new technologies), performance validation, policy benefits, and seasonal market movements, with a focus on innovative drugs and CXO in the short term [6] - AI in healthcare and pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs are identified as high-potential sub-themes [6] - Continuous attention is required on the outcomes of collaborations post-JPM conference, clinical data of innovative drugs, and performance realization [6] Investment Strategy for 2026 - The investment focus in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion [7] - The clinical value is expected to command higher premiums, leading to a favorable outlook on the innovative drug supply chain and innovative medical devices [7]

Core Viewpoint - The Chinese innovative drug sector is experiencing rapid growth, positioning itself as a global leader in drug development, with significant investments and collaborations from major pharmaceutical companies [2][8][30]. Group 1: Market Dynamics - The price of experimental monkeys has surged from 3,000 yuan to 100,000 yuan, indicating a high demand in the innovative drug sector [1]. - By 2025, China is projected to rank second globally in new drug clinical trials, with its pipeline accounting for 30% of the global total [2]. - In 2024, Chinese innovative drug companies completed 94 overseas licensing transactions, representing 44% of the national total, with over 100 transactions exceeding $100 billion in the first ten months of 2025 [6][30]. Group 2: Challenges in Traditional Pharmaceutical Sector - The generic drug sector is facing significant challenges, with a projected 5.5% decline in revenue for 2024 and over 30% of companies experiencing losses [5]. - Major pharmaceutical companies are increasingly collaborating with Chinese innovative drug firms to mitigate the risks associated with patent expirations, which could lead to a revenue gap exceeding $300 billion in the next five years [10][30]. Group 3: Advantages of Chinese Innovative Drugs - China offers a cost-effective and efficient environment for drug development, with clinical trial costs significantly lower than in the U.S. [20][21]. - The average time for clinical trial approvals in China has been reduced from 60 to 30 working days, and the average new drug application approval time has decreased to approximately 130 days [14]. - Chinese pharmaceutical companies are increasingly moving from "me-too" and "me-better" drugs to original innovations, with a notable increase in the number of innovative drug projects [27]. Group 4: Global Positioning and Future Outlook - Despite the rapid growth of Chinese innovative drugs, the overall market value of Chinese biotech companies remains significantly lower than their U.S. counterparts, capturing only 5% to 10% of global new drug revenues [30][31]. - Chinese companies are establishing commercial centers in global pharmaceutical hubs to enhance their commercialization capabilities, marking a shift towards becoming major players in the global market [37][38]. - The transition from biotech firms to large multinational pharmaceutical companies is seen as a critical step in the global battle for market share and innovation [38].

Market Overview - The Hong Kong stock market experienced a decline on January 19, with the Hang Seng Index falling by 0.76% [1] - The pharmaceutical sector faced significant losses, particularly in the innovative drug industry, with major stocks like Alibaba Health and others in the AI medical concept continuing to drop [1][10] Innovative Drug Sector Performance - The innovative drug sector saw a broad adjustment, with leading companies experiencing declines: China Biologic Products fell by 6.19%, CanSino Biologics by 3%, and others like Innovent Biologics and Hansoh Pharmaceutical dropped over 4% [1][13] - The Hong Kong Stock Connect Innovative Drug ETF (520880) fell by 2.72%, marking a three-day losing streak and losing both the 10-day and 60-day moving averages, with trading volume increasing by over 50% to 390 million HKD [11][12] Factors Influencing Market Sentiment - The adjustments in the innovative drug sector are attributed to the market digesting sentiments post the JPMorgan Healthcare Conference, which concluded on January 15, and a cautious outlook ahead of upcoming earnings forecasts for 2025 [4][15] - The market is currently in a phase of waiting for actual revenue and profit data, leading to a tendency to avoid uncertainty, particularly for companies that are not yet profitable or are in the early stages of commercialization [4][15] Future Outlook for Innovative Drug Sector - The innovative drug sector is expected to see significant earnings forecasts from leading companies in 2025, which could present opportunities for valuation recovery if results exceed expectations [5][16] - The sector's long-term fundamentals remain strong, with projections indicating that the total overseas licensing revenue for innovative drugs could reach 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [16] - Continued policy support is anticipated, with the National Medical Products Administration expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the review and approval processes [16] Investment Strategy - The Hong Kong Stock Connect Innovative Drug ETF (520880) is positioned as a high-elasticity T+0 investment tool, focusing exclusively on innovative drug R&D companies [5][16] - The ETF's index features a significant concentration of leading companies, with the top ten holdings accounting for over 73% of the total weight, indicating a strong representation of the sector's core strengths [6][17]

智通财经记者 | 黄华 1月上旬，据港交所信披，浙江博锐生物制药股份有限公司（文中简称"博锐生物"）已提交上市申请， 联席保荐人为华泰国际和摩根大通。 博锐生物在医药行业小有名气，它由老牌药企海正药业孵化，前身是海正药业的生物制剂业务部门，于 2019年1月起重组为有限公司。据招股书披露，PAG Highlander（太盟投资集团）及海正药业直接持股 44.62%、39.62%。 在2022年1月接受《21世纪经济报道》专访时，博锐生物时任首席执行官（CEO）王海彬表示，希望企 业会在未来成为全球性的免疫疾病领域龙头。就现阶段而言，博锐生物有不少自免药物，也确实是自 免"大药"阿达木单抗生物类似药的销冠，但距离全球龙头目标尚远，尤其是企业在创新药和国际化方面 只能说是刚刚起步。 1月7日，就博锐生物的IPO动态，智通财经向企业发送了采访邮件。截至发稿时，尚未收到回复。 是阿达木单抗国内销冠 博锐生物是国内隐形的生物药大户，代表产品为阿达木单抗（商品名：安健宁®）。 阿达木单抗是艾伯维公司开发的自免领域生物药，曾11年蝉联全球药王。凭借难以超越的商业成就，原 研商品名修美乐几乎能和药王画上等号。该产品于2003 ...

Market Overview - The Hong Kong stock market experienced a decline, with all three major indices dropping over 1%. The Hang Seng Index fell by 1.05% to 26,563.9 points, with a total trading volume of 225.69 billion HKD [1] - Huatai Securities noted that the core factors driving the market rebound in the first quarter remain unchanged, including overall loose financial conditions and improved profit expectations, suggesting continued opportunities for investment in Hong Kong stocks [1] Blue-Chip Stocks Performance - Li Ning (02331) reached a new high, closing up 2.94% at 21 HKD, contributing 2.21 points to the Hang Seng Index. Morgan Stanley forecasts moderate revenue growth for Li Ning by 2025, with net profit margins stabilizing at high single digits [2] - Other blue-chip stocks included Sinopec (00386) up 3.34% and Mengniu Dairy (02319) up 2.78%, while China Biologic Products (01177) fell 6.19% and Innovent Biologics (01801) dropped 4.64%, negatively impacting the index [2] Sector Highlights Aviation Stocks - Aviation stocks performed well, with China Eastern Airlines (00670) up 9.2%, China Southern Airlines (01055) up 6.29%, and Air China (00753) up 3.76%. The 2026 Spring Festival travel period is expected to see a passenger volume of 95 million, a 5.3% increase year-on-year [3] Power Equipment Stocks - Power equipment stocks rose, with Dongfang Electric (01072) up 6.38% and Harbin Electric (01133) up 5.46%. The National Energy Administration announced that China's electricity consumption is projected to exceed 10 trillion kWh by 2025, a 5% year-on-year increase [4] Gold Stocks - Gold stocks were active, with Zhaojin Mining (01818) up 3.62% and Zijin Mining (02259) up 2.47%. The international gold price surged to a historical high of 4,690 USD per ounce due to rising market risk aversion stemming from escalating US-EU tariff disputes [5] Earnings Forecasts - Companies with positive earnings forecasts saw strong performance, including Qutoutiao (00917) up 38.78% and TCL Electronics (01070) up 13.4%. Qutoutiao expects to turn a profit with a net income between 270 million to 330 million RMB for the fiscal year ending December 31, 2025 [6] Notable Stock Movements - New World Development (00017) surged 16.28% to 11.07 HKD, reaching a two-year high, as the company’s chairman expressed confidence in creating value through strategic investments [7] - UBTECH Robotics (09880) rose 8.63% after signing a service agreement with Airbus for humanoid robots [8] - China National Offshore Oil Corporation (01138) climbed 7.39% amid favorable conditions in the oil transportation market due to geopolitical changes [9] - China Duty Free Group (01880) increased by 6.65% following strong growth in duty-free shopping in Hainan [10] - Cambridge Technology (06166) fell 12.2% after reporting lower-than-expected fourth-quarter profits despite a projected annual profit increase [11]